View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 17, 2011

FDA clears CorMatrix carotid tissue repair implant

CorMatrix Cardiovascular has received US Food and Drug Administration (FDA) 510(k) clearance for its CorMatrix ECM, a device designed for pericardial closure and carotid tissue repair following endarterectomy and suture line buttressing.

CorMatrix Cardiovascular has received US Food and Drug Administration (FDA) 510(k) clearance for its CorMatrix ECM, a device designed for pericardial closure and carotid tissue repair following endarterectomy and suture line buttressing.

CorMatrix ECM uses the company’s proprietary ECM technology, an extracellular matrix biomaterial which provides a natural bio-scaffold, enabling a patient’s own host cells to repopulate and repair damaged tissues.

The unique CorMatrix material helps stimulate tissue growth by providing a location where the patient’s cells can migrate and integrate, eventually creating new tissue in place of the CorMatrix ECM.

The CorMatrix implant is gradually replaced, as the patient’s own body reinforces and rebuilds the weakened site.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management